PubMed Health⌕ Search

PubMed · 16658850

Structure and function of developing barley plastids.

Abstract

Five different regions of the first foliage leaf of etiolated barley seedlings were studied with respect to leaf growth, plastid growth and replication, differentiation of etioplasts, and conversion of etioplasts into chloroplasts upon illumination. Ultrastructural changes of the plastids were correlated with chlorophyll synthesis and development of photosynthetic activity as measured by (14)CO(2) incorporation and O(2) evolution. The first foliage leaf has greater linear growth over a longer period of time in the dark than in the light. Only the bottom two regions (4 and 5) are still growing in the 5-day etiolated leaf. Region 4 grows by cell elongation, and region 5 grows by both cell division and elongation. Plastids in all five regions of the leaf are capable of enlarging when exposed to light. This is true both for the intact plant and for excised sections. Plastid replication occurs predominantly in the younger regions of the leaf (regions 3, 4, and 5). The amount of chlorophyll synthesized by different regions in the intact plant is significantly higher (3-40 times) than that made by excised sections. Ultrastructural changes occurring in each region when excised sections are illuminated were classified into five stages involving increased membrane synthesis and appression into grana, and these changes were correlated with the first appearance of photosynthetic activity. The earliest detectable photosynthetic activity occurs in region 1 after 2 hours of illumination when chloroplasts show only a few overlaps in the thylakoids. Plastids in younger regions of the leaf require up to 24 hours of light to form grana and develop photosynthetic activity. Plastids in each region of the leaf are in different stages of development when photosynthesis is initiated, indicating that development of photosynthetic activity is not strictly correlated with a certain stage of plastid development. Membrane appression is not indicative of photosynthetic activity since overlaps are formed in the dark, but it was always present when photosynthetic activity was detectable. Likewise, there does not appear to be any strict correlation between the presence of chlorophyll and membrane appression. These results show that the particular structural and functional correlations that can be made depend to a large degree on age of the tissue.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Robertson, W M Laetsch. 1974. Structure and function of developing barley plastids.. https://doi.org/10.1104/pp.54.2.148

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗